Popular Trials
Macrolide Antibiotic
Azithromycin for Cystic Fibrosis
Pulmonary infection with Burkholderia cepacia complex (BCC) in patients with CF is often associated with a more rapid decline in lung function. Because of the resistance of BCC to many antibiotics, treatment options are often limited. New therapies to improve outcomes for patients infected with BCC are needed. However, because of the unpredictable nature of this pulmonary infection in CF, patients with BCC infection have been excluded from many CF therapeutic trials. Recent published trials in the United States, Australia, and the United Kingdom have all demonstrated clinical benefits from prolonged administration of azithromycin in CF. In these trials, the vast majority of patients were chronically infected with Pseudomonas aeruginosa. Patients with BCC were excluded from the US and UK trials, and only four patients with BCC infection were enrolled in the Australian trial. Thus, the effectiveness of azithromycin in CF patients infected with BCC is largely unknown and deserves further study. The two main ways by which azithromycin is thought to help with the chronic lung infections seen in CF are by \[a\] reducing inflammation and \[b\] direct effects on the bacteria, in particular P. aeruginosa. BCC pulmonary infection in CF is often associated with a large inflammatory response similar to or more severe than P. aeruginosa infection. If azithromycin works mainly by an anti-inflammatory mechanism, it should also be helpful in CF patients infected with BCC. Alternatively, azithromycin could have a direct effect on BCC as seen with P. aeruginosa as the two bacteria have many similarities.
Cell Therapy
Autologous Skeletal Myoblasts for Cardiomyopathy
The purpose of this study is to evaluate the safety and effectiveness of injecting myoblasts (grown from your own skeletal muscle), using a catheter device, directly into the damaged heart muscle for treatment of severe heart failure.
Anti-metabolites
Fludarabine +2 More for Graft Failure
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (\<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an allogeneic SCT from an HLA-Identical or non-identical family donor or unrelated donors, with fludarabine (150mg/m2) and TBI (400cGy), with post-transplantation immunosuppression utilizing tacrolimus and MMF. B. To evaluate the incidence of transplant related mortality. Minor Objectives A. To evaluate the incidence of acute and chronic GVHD after second allogeneic HCT utilizing Tac/MMF with peripheral blood stem cells from matched or mis-matched allogeneic donors. B. To evaluate disease responses and survival after second allogeneic SCT. C. To evaluate the need for DLI after second transplant for either disease control or persistent mixed chimerism.
Popular Filters
Trials for HIV Patients
Antiretroviral Agent
Enfuvirtide for Human Immunodeficiency Virus Infection
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.
Bisphosphonates
Zoledronate +1 More for Human Immunodeficiency Virus Infection
Bisphosphonates are a type of drug used to prevent and treat bone loss. The purpose of this study is to determine if zoledronate, an investigational bisphosphonate, can improve bone mineral density (BMD) in HIV-infected adults. Study hypothesis: Zoledronate will reduce bone resorption in HIV-infected persons with osteopenia.
Virus Therapy
Oral HIV Vaccine Safety for HIV Prevention
This trial will test a new oral HIV vaccine for safety and effectiveness. The vaccine uses a weakened form of Salmonella to deliver an HIV gene into the body, stimulating an immune response. The vaccine cannot cause HIV.
Virus Therapy
Polyvalent HIV-1 Vaccine for Human Immunodeficiency Virus Infection
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
Trials for Human Immunodeficiency Virus Infection Patients
Antiretroviral Agent
Enfuvirtide for Human Immunodeficiency Virus Infection
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.
Bisphosphonates
Zoledronate +1 More for Human Immunodeficiency Virus Infection
Bisphosphonates are a type of drug used to prevent and treat bone loss. The purpose of this study is to determine if zoledronate, an investigational bisphosphonate, can improve bone mineral density (BMD) in HIV-infected adults. Study hypothesis: Zoledronate will reduce bone resorption in HIV-infected persons with osteopenia.
Virus Therapy
Oral HIV Vaccine Safety for HIV Prevention
This trial will test a new oral HIV vaccine for safety and effectiveness. The vaccine uses a weakened form of Salmonella to deliver an HIV gene into the body, stimulating an immune response. The vaccine cannot cause HIV.
Virus Therapy
Polyvalent HIV-1 Vaccine for Human Immunodeficiency Virus Infection
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
Phase 3 Trials
Cancer Vaccine
Botanical Supplement for Lung Cancer
This trial is testing whether a dietary supplement consisting of botanicals with known anti-cancer and/or immune-enhancing properties can prolong the survival time of stage IIIB/IV non-small cell lung cancer patients. The supplement will be given to patients in a double-blind fashion, meaning that neither the patients nor the trial staff will know who is receiving the supplement and who is receiving a placebo.
Insulin
Generex Oral-lynâ„¢ for Diabetes
To compare the efficacy of Generex Oral-lynâ„¢ RapidMistâ„¢ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.
Nanoparticle
nano-silver gel +1 More for Normal Subjects
The purpose of this pilot study is to compare the antimicrobial efficacy of silver nanoparticle gel to a commercialized alcohol-based hand gel on bacterial counts isolated from the hands of 40 volunteers seeded with Serratia marcescens, a surrogate microbial marker. Specific aims of this study are: Aim #1: Compare the immediate antimicrobial efficacy of a one-time application of silver nanoparticle gel (SilvaSorb , AcryMed, Inc., Portland, OR) versus an alcohol-based hand gel (Purell, GoJo Industries, Akron, OH) in reducing transient bacterial counts isolated from hands seeded with S. marcescens. Aim # 2: Compare the persistent antimicrobial efficacy of a one-time application of silver nanoparticle gel (SilvaSorb) versus an alcohol-based hand gel (Purell) over a 10 minute time frame in producing a persistent reduction on transient bacterial counts isolated from hands seeded with S. marcescens. Aim # 3: Compare user acceptability of silver nanoparticle gel (SilvaSorb) versus an alcohol-based hand gel (Purell) using a self-assessment questionnaire.
Probiotic
Bifidobacterium lactis HN019 for Influenza
To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
Behavioral Intervention
Couplelinks.ca website for Breast Cancer
Women diagnosed with breast cancer (BC) at or before the age of 50 experience more distress and poorer quality of life than women diagnosed later in life. Although adequate spousal support is a protective factor for women with BC, spouses are often unprepared to handle the myriad practical and emotional demands posed by the illness. Furthermore, despite the growing number of recommendations for couple interventions in relation to BC, traditional counselling approaches may fail to meet the needs of young couples who have unique concerns and tight constraints on their time. The proposed project addresses the void in the psycho-social support available to young couples via an innovative, online psychoeducational intervention tailored specifically to their needs.
Trials With No Placebo
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Antiretroviral Agent
Enfuvirtide for Human Immunodeficiency Virus Infection
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.
Virus Therapy
Oral HIV Vaccine Safety for HIV Prevention
This trial will test a new oral HIV vaccine for safety and effectiveness. The vaccine uses a weakened form of Salmonella to deliver an HIV gene into the body, stimulating an immune response. The vaccine cannot cause HIV.
Virus Therapy
Polyvalent HIV-1 Vaccine for Human Immunodeficiency Virus Infection
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
Probiotic
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 for Urinary Tract Infection
Many children who catheterize their bladders because of spina bifida or other neurologic disorders have bacteriuria. This can lead to urinary tract infections by bacteria from the gut which colonize the vagina and are carried into the bladder during catheter passage. We seek to test whether oral administration of probiotic bacteria can "displace" these vagina-derived uropathogens and reduce or prevent bacteriuria in girls with spina bifida who empty their bladders through catheterization.
Insulin
Generex Oral-lynâ„¢ for Diabetes
To compare the efficacy of Generex Oral-lynâ„¢ RapidMistâ„¢ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.
View More Related Trials
Frequently Asked Questions
Introduction to cte
What are the top hospitals conducting cte research?
Chronic Traumatic Encephalopathy (CTE) is a complex neurodegenerative condition that has gained significant attention in recent years due to its association with repeated head injuries, particularly in contact sports. In the quest for understanding and finding effective treatments for CTE, top hospitals are leading the way in conducting clinical trials. Among these institutions is the esteemed Dana-Farber Cancer Institute based in Boston. With five ongoing CTE trials, they are at the forefront of research into this debilitating condition. Similarly, Memorial Sloan Kettering Cancer Center in New york also prioritizes CTE research with an equal number of active trials aimed at unraveling the complexities surrounding this disorder.
Adding to these efforts is Tufts Medical Center, another renowned hospital located in Boston, where four active clinical trials focusing on CTE are currently underway. Not limited to just one region, two other notable locations involved in combating CTE through clinical research include a Research Site based out of New York and another situated in Montreal—each contributing three ongoing clinical trials dedicated to uncovering new insights about this challenging condition.
It's important to note that while these hospitals have made significant contributions by initiating several active studies related to CTE treatment and understanding; there hasn't been any recorded completed trial as yet highlighting how crucial it remains for further exploration into potential interventions or preventive measures against this progressive neurological disorder affecting individuals exposed to repetitive brain trauma.
The dedication shown by these institutions reflects their commitment not only toward alleviating the suffering caused by CTE but also fostering scientific progress that could reshape our approach towards preventing long-term consequences associated with traumatic brain injuries. By driving forward innovative research initiatives focused on improving our knowledge surrounding chronic traumatic encephalopathy, they offer hope for future generations impacted by head trauma and inspire collective efforts aimed at safeguarding athletes' well-being worldwide
Which are the best cities for cte clinical trials?
When it comes to clinical trials for chronic traumatic encephalopathy (CTE), several cities emerge as top contenders in research and development. New york, with 30 active trials, focuses on investigating treatments like Pembrolizumab and SRS, PF-07062119, among others. Los Angeles follows closely behind with 19 ongoing studies exploring interventions such as Durvalumab, Abemaciclib, and patients diagnosed with pulmonary arterial hypertension (PAH) or CTEPH. Atlanta boasts 17 active trials examining options like palliative radiation therapy, Maraviroc, ALIS, and more. Lastly, Chicago offers 16 active trials that delve into treatments including oral Cabotegravir (CAB), Durvalumab, Trastuzumab deruxtecan. Together these cities provide access to cutting-edge clinical trials for individuals battling CTE across the United States.
Which are the top treatments for cte being explored in clinical trials?
Clinical trials are actively exploring several promising treatments for Chronic Traumatic Encephalopathy (CTE). The top contenders in these trials include:
- Treatment A: Currently being tested in X number of active CTE trials and Y number of all-time clinical trials.
- Treatment B: Under investigation in Z number of ongoing CTE studies and W number of all-time clinical trials.
- Treatment C: Showing potential with Q number of active CTE trials and R number of all-time clinical trials.
These innovative treatments offer hope for those affected by this debilitating condition, as researchers continue their relentless pursuit to find effective therapies for CTE.
What are the most recent clinical trials for cte?
Promising developments in clinical trials offer hope for those affected by chronic traumatic encephalopathy (CTE). One significant trial involves ASKG915, a potential treatment currently undergoing Phase 1 testing. Additionally, LB2102 is an experimental therapy showing promise in its Phase 1 trial for CTE patients. Immunotherapy has also emerged as a potential avenue, with the combination of avelumab and lurbinectedin being evaluated during Phase 2 trials. The TAK-861 Dose 1 trial has advanced to both Phase 2 and Phase 3 stages, offering further possibilities for effective CTE treatments. These recent clinical trials provide optimism that innovative therapies will soon be available to improve the lives of individuals living with CTE.
What cte clinical trials were recently completed?
Recently completed clinical trials for chronic traumatic encephalopathy (CTE) are paving the way for enhanced understanding and potential treatments of this debilitating condition. Notably, a trial sponsored by Washington University School of Medicine was concluded in October 2021, focusing on addressing key aspects of CTE. The dedication to research is evident as scientists strive to unlock new insights into the complexities of CTE and develop strategies that could bring hope to individuals affected by this neurodegenerative disease.